Myelodysplastic Syndromes, Version 2.2015

View More View Less
  • 1 From Stanford Cancer Institute; Dana-Farber/Brigham and Women’s Cancer Center; UC San Diego Moores Cancer Center; University of Rochester Medical Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; University of Alabama at Birmingham Comprehensive Cancer Center; Duke Cancer Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Massachusetts General Hospital Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; UCSF Helen Diller Family Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Roswell Park Cancer Institute; Vanderbilt-Ingram Cancer Center; Memorial Sloan Kettering Cancer Center; Moffitt Cancer Center; University of Michigan Comprehensive Cancer Center; Fred & Pamela Buffett Cancer Center; City of Hope Comprehensive Cancer Center; University of Colorado Cancer Center; Huntsman Cancer Institute at the University of Utah; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.
Restricted access

The NCCN Guidelines for Myelodysplastic Syndromes (MDS) comprise a heterogeneous group of myeloid disorders with a highly variable disease course that depends largely on risk factors. Risk evaluation is therefore a critical component of decision-making in the treatment of MDS. The development of newer treatments and the refinement of current treatment modalities are designed to improve patient outcomes and reduce side effects. These NCCN Guidelines Insights focus on the recent updates to the guidelines, which include the incorporation of a revised prognostic scoring system, addition of molecular abnormalities associated with MDS, and refinement of treatment options involving a discussion of cost of care.

Provided content development and/or authorship assistance.

Supplementary Materials

    • Supplemental Material (PDF 234 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 206 145 6
PDF Downloads 58 46 1
EPUB Downloads 0 0 0